EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

Geert D'Haens iD, Peter D R Higgins, Laurent Peyrin-Biroulet, Bruce E Sands, Scott Lee, Richard E Moses, Isabel Redondo, Rodrigo Escobar, Theresa Hunter Gibble iD, Anthony Keohane, Nathan Morris, Xin Zhang und 2 weitere

Inflammatory Bowel Diseases · 05.12.2024 · 30 (12) · 2335-2346

DOI: 10.1093/ibd/izae004 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 25.01.2024. Verfasst von Geert D'Haens und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Inflammatory Bowel Disease Centre, Amsterdam University Medical Center, Meibergdreef 9, C2-208, 1105 AZ Amsterdam, th…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Severity of Illness Index. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Efficacy and safety of mirikizumab, a p19-targeted anti-interleukin-23 monoclonal antibody, for moderately to severely active ulcerative colitis was demonstrated previously. We evaluated clinical response, baseline characteristics, and clinical status in patients not responding by 12 weeks (W) of induction who then received extended induction treatment.

Method

Patients unresponsive to 300 mg of intravenous (IV) mirikizumab every 4 weeks by W12 received 3 additional 300 mg IV doses every 4 weeks. Week-4 responders received 200 mg mirikizumab every 4 weeks subcutaneously until W52. Patients responding by W12 but subsequently losing response received rescue therapy with 300 mg IV for 3 doses every 4 weeks. Logistic regression modelling was performed for patients not achieving W12 clinical response to assess baseline characteristics and W12 efficacy parameters and potential prognostic factors of clinical response at W24.

Results

Of patients not achieving clinical response during induction, 53.7% achieved response following extended induction. After 52W, 72.2%, 43.1%, and 36.1% of patients achieved clinical response, endoscopic, and clinical remission, respectively. Of induction responders who subsequently lost response, 63.2% and 36.8% achieved symptomatic response and remission, respectively, after receiving rescue therapy No prior biologic or tofacitinib treatment, no immunomodulators at baseline, age older than 40 years, and W12 modified Mayo Score improvement were positively associated with a response to extended induction. The safety profile was similar to initial induction, with 38.3% treatment emergent adverse events, mostly mild.

Conclusion

With “extended induction,” total of 80.3% mirikizumab-treated patients achieved clinical response by W24. Potential prognostic factors determining response include disease severity, disease phenotype, C-reactive protein, and previous biologic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeSeverity of Illness IndexAdultFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedInduction ChemotherapyInterleukin-23 Subunit p19PrognosisRemission InductionTreatment Outcome

Stichwörter der Autor:innen

IL-23 antibodiesextended inductionmirikizumabulcerative colitis

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-23 Subunit p19

Autor:innen und Institutionen

  • Department of Gastroenterology, Inflammatory Bowel Disease Centre, Amsterdam University Medical Center, Meibergdreef 9, C2-208, 1105 AZ Amsterdam, the Netherlands.
  • Gastroenterology Clinic, Taubman Center, 1500 E Medical Center Dr, University of Michigan, Ann Arbor, MI, USA.
  • Department of Gastroenterology, University of Lorraine, CHRU-Nancy, France.
  • University of Lorraine, Inserm, NGERE, F-54000 Nancy, France.
  • Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Geert D'Haens, Theresa Hunter Gibble, Taku Kobayashi

Förderung

  • NIDDK NIH HHS
  • Eli Lilly and Company

Zitieren

APA

D'Haens, G., Higgins, P. D. R., Peyrin-Biroulet, L., Sands, B. E., Lee, S., Moses, R. E., Redondo, I., Escobar, R., Hunter Gibble, T., Keohane, A., Morris, N., Zhang, X., Arora, V., & Kobayashi, T. (2024). Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials. Inflammatory Bowel Diseases, 30(12), 2335-2346. https://doi.org/10.1093/ibd/izae004

Vancouver

D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, et al. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials. Inflammatory Bowel Diseases. 2024;30(12):2335-2346. doi:10.1093/ibd/izae004

BibTeX
@article{DHaens2024,
  author = {D'Haens, Geert and Higgins, Peter D R and Peyrin-Biroulet, Laurent and Sands, Bruce E and Lee, Scott and Moses, Richard E and Redondo, Isabel and Escobar, Rodrigo and Hunter Gibble, Theresa and Keohane, Anthony and Morris, Nathan and Zhang, Xin and Arora, Vipin and Kobayashi, Taku},
  title = {Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {12},
  pages = {2335--2346},
  doi = {10.1093/ibd/izae004}
}
Kostenlos starten →